Horizons in Cancer Research. Volume 86


Hiroto S. Watanabe (Editor)

Series: Horizons in Cancer Research
BISAC: MED062000

This volume contains nine chapters that detail horizons in cancer research. Chapter One summarizes the role of epigenetic modifications in altering the phenotype of the tumor immune microenvironment. Chapter Two defines the current trends in cancer therapy and the challenges that come with them. Chapter Three discusses the toxicities of tyrosine kinase inhibitors used in the treatment of hepatocellular carcinoma. Chapter Four proposes a multifaceted approach to the lymphedema assessment that extends beyond arm size and volume based outcomes, and considers the impact of the condition on the individual and their life participation. Chapter Five elucidates the clinical features and diagnostic criteria of osteoradionecrosis of the jaw and emphasizes the essential measures required to overcome the difficulties associated with its diagnosis, utilizing the latest available differential diagnosis information. Chapter Six reviews the potent anticancer activity of the xanthohumol (XN) molecule and its analogs. Chapter Seven reviews recent preclinical and clinical studies to examine the current position of nanoparticle drug delivery systems in the treatment of peritoneal carcinomatosis. Chapter Eight summarizes the pivotal role of the SphK/S1P axis in modulating estrogen related signaling cascade during the breast cancer progression and develops the promising therapeutic strategies for BCs by targeting the SphK/S1P axis. Lastly, Chapter Nine summarizes the current studies of S1P/S1PR signaling in bone metastasis and aims to establish a theoretical basis for the application of S1P/S1PR in the treatment of bone metastasis.

Table of Contents


Chapter 1. The Epigenetic Regulation of the Tumor Immune Microenvironment: The Role of Epi-Drugs and Epi-Diets
Bhavjot Kaur¹, MSc and Syed Musthapa Meeran¹,², PhD
¹Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysuru, Karnataka, India
²Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India

Chapter 2. New Advances and Challenges in Cancer Therapeutics
V. S. Soumya¹,², Gayathri S. Kamath¹, Anjana Suresh¹, Nikhila Leemon¹ and Sreejith Parameswara Panicker¹
¹Department of Zoology and Advanced Centre for Regenerative Medicine and Stem Cell in Cutaneous Research (AcREM-Stem), University of Kerala, Karyavattom, Thiruvananthapuram, India
²St. Stephen’s College, Pathanapuram, Affiliated with the University of Kerala, Kollam, India

Chapter 3. Toxicities of Tyrosine Kinase Inhibitors Used in the Treatment of Hepatocellular Carcinoma
Aysenur Gunaydin-Akyildiz, PhD
Bezmialem Vakif University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul, Turkey

Chapter 4. A Comprehensive Assessment to Inform Clinical Decision-Making for the Conservative Management of Breast Cancer Related Lymphedema
Margaret L. McNeely¹,², Shirin M. Shallwani¹, Mona M. Al Onazi¹, Paula A. Ospina¹, Joanna F. Parkinson¹ and Naomi Dolgoy³
¹Department of Physical Therapy, University of Alberta, Edmonton, Alberta, Canada
²Supportive Care Services, Cancer Care Alberta, Canada
³Department of Occupational Therapy, University of Alberta, Edmonton, Alberta, Canada

Chapter 5. Clinical Diagnostics of Osteoradionecrosis of the Jaw
Busra Yilmaz¹, MSc, DDS, Elif Celebi¹, MSc, DDS, Elif Merve Ozcan², PhD, DDS, Ali Ayberk Besen³, MD, Huseyin Mertsoylu³, MD, Ugur Selek⁴, MD, Berrin Pehlivan,⁵MD and Erkan Topkan⁶, MD
¹Department of Oral and Maxillofacial Radiology, Bahcesehir University School of Dental Medicine, Istanbul, Turkey
²Department of Oral and Maxillofacial Surgery, Bahcesehir University School of Dental Medicine, Istanbul, Turkey
³Department of Medical Oncology, Istinye University, Medical Park Hospital, Adana, Turkey
⁴Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey
⁵Department of Radiation Oncology, Bahcesehir University School of Medicine, Istanbul, Turkey
⁶Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana, Turkey

Chapter 6. Xanthohumol, a Prenylated Chalcone from Nature: Synthesis, Isolation and Anticancer Activity
Manos C. Vlasiou
University of Nicosia, Nicosia, Cyprus

Chapter 7. Nanoparticles for the Treatment of Peritoneal Carcinomatosis
İrem Karasu¹, MPharm, Sakine Ulusoy¹,², MSc, Göksu Yağ Çiligiroğlu¹, MSc and Adem Şahin¹,³, PhD
¹Department of R&D, Centurion Pharma, Ankara, Turkey
²Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
³Department of Pharmacy Service, Vocational School of Health Services, Bilecik Seyh Edebali University, Bilecik, Turkey

Chapter 8. The Pivotal Therapeutic Target of Sphingosine-1-Phosphate and Sphingosine Kinase Signaling in Breast Cancer
Yiran Wang
Department of Obstetrics and Gynecology, General Hospital of Western Theater Command of Chinese People’s Liberation Army, Chengdu, China

Chapter 9. The Promising Targets in Bone Metastasis of Cancer: Sphingosine-1-Phosphate and Its Receptors
Chuan Yang¹, Tingwen Xiang² and Yueqi Chen³
¹Department of Biomedical material, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China
²College of Basic Medical Science, Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China
³Department of Orthopedics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China


Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!